Researcher.Life Logo

Annals of the Rheumatic Diseases : Impact Factor & More

eISSN: 1468-2060pISSN: 0003-4967

Aims and Scope of Annals of the Rheumatic Diseases

The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less

Key Metrics

CiteScore
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases Journal Specifications

Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1935
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of the Rheumatic Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of the Rheumatic Diseases

Correspondence on 'Rheumatology and Long COVID: lessons from the study of fibromyalgia?' by Clauw and Calabrese.
  • 27 Dec 2025
  • Annals of the rheumatic diseases
Identification of novel fibroblast subsets in diffuse cutaneous systemic sclerosis.
  • 27 Dec 2025
  • Annals of the rheumatic diseases
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.
  • 20 Dec 2025
  • Annals of the rheumatic diseases
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multiomics analysis.
  • 18 Dec 2025
  • Annals of the rheumatic diseases
Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis.
  • 17 Dec 2025
  • Annals of the rheumatic diseases
Th9-arterial endothelial cell crosstalk promotes psoriatic atherosclerosis.
  • 12 Dec 2025
  • Annals of the rheumatic diseases
Correspondence on 'Rheumatology and Long COVID: lessons from the study of fibromyalgia?' by Clauw and Calabrese.
  • 27 Dec 2025
  • Annals of the rheumatic diseases
Identification of novel fibroblast subsets in diffuse cutaneous systemic sclerosis.
  • 27 Dec 2025
  • Annals of the rheumatic diseases
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.
  • 20 Dec 2025
  • Annals of the rheumatic diseases
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multiomics analysis.
  • 18 Dec 2025
  • Annals of the rheumatic diseases
Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis.
  • 17 Dec 2025
  • Annals of the rheumatic diseases
Th9-arterial endothelial cell crosstalk promotes psoriatic atherosclerosis.
  • 12 Dec 2025
  • Annals of the rheumatic diseases

FAQs on Annals of the Rheumatic Diseases